EV/EBITDA spoločnosti Agios Pharmaceuticals Inc

Aká je hodnota metriky EV/EBITDA spoločnosti Agios Pharmaceuticals Inc?

Hodnota metriky EV/EBITDA spoločnosti Agios Pharmaceuticals Inc je N/A

Aká je definícia metriky EV/EBITDA?



EV/EBITDA je podniková hodnota vydelená EBITDA (zisk pred odpočítaním úrokov, daní, odpisov, a amortizácie). Meria nákladnosť akcie a používa sa na porovnávanie spoločností medzi sebou častejšie ako P/E ratio. Meria cenu akú investor zaplatí za pohyb hotovosti v spoločnosti.

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

EV/EBITDA spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Agios Pharmaceuticals Inc

Čomu sa venuje spoločnosť Agios Pharmaceuticals Inc?

at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible

Firmy s metrikou ev/ebitda podobnou spoločnosti Agios Pharmaceuticals Inc